BioMarin

In News

What Is Drawing Fresh Attention To BioMarin Pharmaceutical (BMRN)? - Yahoo Finance

Yahoo Finance - Sep 19, 2026

BioMarin drops Voxzogo development for Noonan syndrome as treatment landscape shifts - Fierce Pharma

Fierce Pharma - Sep 15, 2026

What BioMarin Pharmaceutical Shares' Phase 3 Growth Data Means For Shareholders - simplywall.st

simplywall.st - Sep 17, 2026

BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors - PR Newswire

PR Newswire - Sep 14, 2026

BioMarin options flow shows large bullish call spread targeting $100 by April 2027 - Investing.com

Investing.com - Sep 17, 2026

The Escalator: Legend Biotech, BioMarin, Turn Therapeutics and more - Medical Marketing and Media

Medical Marketing and Media - Sep 17, 2026

BioMarin Pharmaceutical stock holds near a $12.38 billion value - AD HOC NEWS

AD HOC NEWS - Sep 20, 2026

BioMarin axes $270M rare disease asset after missing phase 3 endpoint - Fierce Biotech

Fierce Biotech - Aug 07, 2026

BMRN Stock Rises On Up To $490M Alesta Deal, But Analyst Cuts Price Target To $59 — Here’s Why - Stocktwits

Stocktwits - Sep 19, 2026

Biomarin nabs big royalties in achondroplasia patent settlement with Ascendis - BioSpace

BioSpace - Aug 31, 2026

BioMarin shelves Voxzogo in Noonan syndrome (BMRN:NASDAQ) - Seeking Alpha

Seeking Alpha - Sep 15, 2026

BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors - Investing News Network

Investing News Network - Sep 14, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment